Neeraj Narula

Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Background and Aims We assessed placebo rates and associated factors using individual patient data (IDP) from randomized clinical trials (RCTs) in ulcerative colitis (UC). Methods We conducted an IPD meta-analysis using Vivli and Yale University Open Data Access data-sharing platforms. Phase 2 and 3 RCTs of advanced biologics in adults with moderate-to-severe UC published since 2010 were included. Pooled placebo rates and 95% CIs were estimated using one- and two-stage meta-analytical approaches. Significant patient-level factors (P < .05) were identified using regression analyses. Primary outcomes were clinical response and remission. Results Data were available for 1703 patients from nine studies. For induction trials, overall placebo response and remission rates were 33% (95% CI 29%-38%) and 9% (95% CI 7%-11%). Overall placebo response and remission rates in maintenance trials were 28% (95% CI 18%-41%) and 14% (95% CI 9%-20%). A lower body mass index reduced the odds of placebo response and remission, while higher baseline albumin levels and left-sided (compared to extensive) UC increased the odds of these outcomes. A 1-point increase in the Mayo Clinic Score (MCS) and adapted MCS was associated with a 26% and 27% reduction in odds of clinical remission. For induction trials, prior biologic exposure was associated with lower odds of response and remission. Multicenter trials have lower placebo effects than single-center trials. Conclusions These results enable future trials to incorporate design elements that reduce placebo rates as well as a precise benchmark for expected rates in clinical trials that do not include placebo.

Year:

2025

Introduction Eosinophils may contribute to ulcerative colitis (UC) pathogenesis through inflammation and epithelial injury. Mirikizumab, a selective IL-23 inhibitor, has shown efficacy in moderate-to-severe UC. However, the relationship between eosinophils and treatment outcomes with IL-23 inhibition remains unclear. Objective This post-hoc analysis of the LUCENT-1 trial evaluated trends in serum and histologic eosinophils as biomarkers for early response to mirikizumab induction therapy in UC. Design Data from LUCENT-1 (NCT03518086) were analyzed to assess serum eosinophil counts and histologic eosinophil presence at baseline and week 12. Clinical response, remission, and endoscopic improvement were defined by modified Mayo score criteria. Logistic regression models, adjusted for factors including steroid use, prior biologic failure, disease severity, and albumin levels, assessed associations between baseline eosinophil levels and treatment outcomes. Results Among 928 participants, 66.6% achieved clinical response. Responders had higher baseline serum eosinophils (0.23 × 109/L vs 0.19 × 109/L, P = .001) and showed greater reductions at week 12. Elevated baseline eosinophils (≥0.57 × 109/L) were associated with higher rates of clinical response (80% vs 65.7%, aOR: 2.31, P = .013), remission (33.3% vs 25.1%, aOR: 1.91, P = .044), and endoscopic improvement (46.7% vs 33.8%, aOR: 2.33, P = .003). Reductions in histologic eosinophils were also linked to improved outcomes, especially in those with moderate/marked baseline presence. Conclusions and Relevance Baseline eosinophil levels may predict response to mirikizumab and guide early treatment decisions. These findings support a potential role for eosinophils as biomarkers in UC management.

Year:

2025

Background Ulcerative colitis (UC) is a chronic inflammatory disease of the colonic mucosa, extending proximally from the rectum. However, the segmental pattern of healing in UC remains unclear. Endoscopic improvement (EI), a key therapeutic endpoint, is typically assessed using the Mayo endoscopic score (MES), which scores the worst affected area and may miss partial/segmental healing. This study evaluates healing patterns in UC and compares conventional MES with a 3-segment MES approach for detecting treatment effects in clinical trials. Methods A post hoc analysis of HIBISCUS I/II and GARDENIA trials was conducted in UC patients with moderate-to-severe disease (MES >2 up to the descending colon). The primary outcome was the proportion of anti-tumor necrosis factor–treated participants achieving MES ≤1 in the descending colon, sigmoid colon, and rectum at week 10. Secondary outcomes included conventionally measured EI, segmental MES improvements, clinical response, and Patient-Reported Outcome 2 (PRO2) normalization. Outcomes were compared between adalimumab, infliximab, and placebo groups. Results Among 300 participants, 217 received infliximab or adalimumab, while 83 received placebo. Healing followed a proximal-to-distal pattern, with the highest EI in the descending colon and the lowest in the rectum. Infliximab-treated patients continued this trend at week 54. Anti-tumor necrosis factor therapy significantly improved EI vs placebo (42.9% vs 19.3%; P < .001). No segmental MES approach outperformed conventional MES for detecting treatment effects. Combined endpoints (MES ≤1 + PRO2 normalization) better captured therapeutic benefits than PRO2 alone (28.6% vs 13.3%; P = .006). Conclusions UC healing follows a proximal-to-distal pattern. Conventional MES remains superior for detecting treatment effects over segmental MES. Further studies should explore alternative endoscopic scoring methodologies.

Year:

2025

Background The modified multiplier of the SES-CD (MM-SES-CD) has been shown to predict future endoscopic healing (EH) in patients with Crohn’s disease. The purpose of this study was to validate baseline MM-SES-CD categories of severity and determine their prognostic value for predicting 1-year EH. Methods Participants in the SEAVUE trial (n = 386) were classified based on baseline endoscopic disease severity using MM-SES-CD cut-offs as mild (≥ 22.5 to < 31), moderate (≥ 31 to < 45), and severe (≥ 45) disease. The primary outcome was achieving 1-year endoscopic healing (EH) as measured by the MM-SES-CD score (< 22.5). Secondary outcomes included clinical and biochemical remission at 1 year based on patient-reported outcomes and fecal calprotectin (FCP)(< 250 mcg/g). Results MM-SES-CD < 22.5 at 1 year was achieved in 62.0% of patients with baseline mild endoscopic disease, 48.6% with moderate disease, and 33.8% with severe disease (P < .001). A similar trend was observed for patient-reported outcome (PRO-2) clinical remission, which was reached in 78.9% of patients with baseline mild endoscopic disease, 72.9% of those with moderate, and 66.2% of those with severe disease (P = 0.09). The likelihood of fecal calprotectin (FCP) remission was significantly associated with baseline endoscopic disease severity (P = .008). Conclusion Baseline MM-SES-CD-based cutoffs for endoscopic disease severity show prognostic value for the likelihood of achieving 1-year EH, PRO2 remission, and FCP remission. These findings suggest that the MM-SES-CD can be used both to measure baseline endoscopic disease severity and predict outcomes at 1 year in patients with moderate to severe CD.

Year:

2025

Background The Simple Endoscopic Score for Crohn’s disease (SES-CD) and Modified Multiplier of the SES-CD (MM-SES-CD) are endoscopic scoring systems used to assess disease severity and response to therapy in CD. This study evaluates their utility at baseline in predicting endoscopic remission (ER) of the ileum and colon at week 52. Methods This post-hoc analysis of 4 clinical trials (CT-P13, UNITI, EXTEND, and SEAVUE) compared baseline scores and ER outcomes at week 52 using the SES-CD and MM-SES-CD. The area under the receiver operating characteristic curve (AUC) for each scoring system’s ability to predict week 52 ER defined by various thresholds was compared. Results A total of 667 patients were included in this analysis. At baseline, the median SES-CD score was 8.5 (IQR 5.0–15.7), and the median MM-SES-CD score was 34.8 (IQR 27.5–50.0). MM-SES-CD demonstrated consistently higher AUC values compared to SES-CD across most endpoints in ileal and colonic disease involvement. Among 519 patients with any disease in the ileum, baseline MM-SES-CD demonstrated significantly better predictive accuracy than SES-CD for week 52 SES-CD < 3 [AUC 0.75 (95% CI: 0.71–0.80) vs. 0.64 (95% CI: 0.59–0.70), P = .031]. Similar findings were observed for other definitions of ER. Among 552 participants with colonic disease involvement, baseline MM-SES-CD also demonstrated significantly greater accuracy for predicting week 52 SES-CD < 3 [AUC 0.78 (95% CI: 0.73–0.82) vs. 0.62 (95% CI: 0.57–0.66), P = .002], with similar findings across other definitions of ER assessed. Similar trends were observed across isolated ileal, ileocolonic, and isolated colonic disease. Conclusion The baseline MM-SES-CD demonstrated superior predictive ability for week 52 ER compared to SES-CD across the ileum and colon. These findings support its utility in clinical trials and in routine practice for predicting long-term treatment response.

Year:

2025

Inflammatory bowel diseases (IBD), Crohn’s disease (CD), and ulcerative colitis (UC) are lifelong chronic, relapsing, and remitting conditions that culminate in disease progression in many patients. Effective management of CD and UC requires consideration of both short- and long-term treatment outcomes. Historically, short-term outcomes such as clinical and endoscopic remission and symptom relief have been evaluated in clinical trials. With the expansion of treatments targeting underlying disease pathophysiology, there is the opportunity to develop management strategies that improve disease control and patients’ lives in both the short and the long term. Researchers have been examining novel outcomes for assessing the efficacy of CD and UC treatments that are important to patients, and also those that go beyond symptomatic improvements or clinical remission. These include new patient-reported outcomes for symptoms, as well as transmural/histological healing and disease clearance that can be more reflective of deeper remission states and disease modification. This review analyses published clinical studies involving patients with UC and CD treated with biologics or small molecule therapies. It highlights novel IBD endpoints employed in published clinical trials and discusses their likely value for assessing disease activity and disease modification, and as predictors of reduced risk of complications and morbidities.

Year:

2025

Introduction In inflammatory bowel disease (IBD), the number of eosinophils increases in the lamina propria of the intestinal tract, but their specific patho-mechanistic role remains unclear. Elevated blood eosinophil counts in active IBD suggest their potential as biomarkers for predicting response to biological therapies. This study evaluates blood eosinophil count trends and their predictive value for clinical response and endoscopic improvement in patients with IBD receiving ustekinumab or adalimumab induction therapy. Methods Participant-level data from phase 3 and 4 clinical trials (UNIFI, SEAVUE, VARSITY) evaluating ustekinumab and adalimumab for moderate–severe Crohn’s disease (CD) and ulcerative colitis (UC) were used. The primary outcome was clinical response, defined by reductions in disease activity scores. Eosinophil counts were compared between responders and non-responders at multiple time points using t-tests. Logistic regression assessed the odds of achieving a clinical response based on baseline eosinophil counts. Results Among patients treated with ustekinumab for UC, responders had significantly higher baseline eosinophil counts compared to non-responders (0.21 × 109/L vs 0.18 × 109/L, P = .042). By week 8, responders showed a greater absolute (−0.07 × 109/L vs −0.01 × 109/L, P < .001) and percent decline (−33.33% vs −5.55%, P = .027) in eosinophil counts. In CD, ustekinumab responders also had higher baseline eosinophil counts and showed significant reductions by week 8. However, no significant differences in eosinophil counts were observed among CD patients treated with adalimumab or UC patients treated with vedolizumab. Conclusion Eosinophil reduction was identified as a marker for early response to ustekinumab in both UC and CD, but not adalimumab. No difference was observed among UC patients treated with vedolizumab either. Targeting the IL-12/IL-23 pathway may be more effective in managing eosinophil-associated inflammation in IBD.

Year:

2025

Introduction The Modified Multiplier of the Simple Endoscopic Score for Crohn’s Disease (MM-SES-CD) refines the assessment of endoscopic CD severity by differentially weighting parameters in the original SES-CD. A threshold of <22.5 for MM-SES-CD suggests endoscopic remission (ER) and correlates with a low risk of long-term disease progression. This study examines whether MM-SES-CD-defined ER and response criteria are more sensitive to treatment effects compared to conventional SES-CD definitions. Methods This post hoc analysis of the EXTEND (extend the safety and efficacy of adalimumab through endoscopic healing) trial compared various SES-CD and MM-SES-CD definitions of ER and endoscopic response in CD patients treated with adalimumab or placebo. The study included participants with moderate–severe CD and a baseline MM-SES-CD score ≥ 22.5. The primary outcome of ER, defined as MM-SES-CD < 22.5, was evaluated at Weeks 12 and 52. Area under the curve (AUC) analyses compared thresholds for predicting Week 52 ER. Results Of the 100 participants (77.5% of the EXTEND population), 51 received adalimumab and 49 received placebo. At Week 12, 62% achieved MM-SES-CD ≥ 20% reduction from baseline, compared to 39% with SES-CD ≥ 50% reduction. At Week 52, 56.9% of adalimumab-treated participants achieved MM-SES-CD < 22.5, compared to 10.2% in the placebo group. Modified Multiplier of the Simple Endoscopic Score for Crohn’s Disease ≥ 20% reduction at Week 12 better predicted Week 52 ER than SES-CD ≥ 50% reduction (AUC: 0.73 vs 0.62, p = 0.002). Conclusion MM-SES-CD definitions improved discrimination between treatment and placebo and offered superior predictive accuracy for Week 52 ER. Its use may enhance trial efficiency and better predict long-term disease outcomes.

Year:

2024

Background The evidence for the management of patients with Crohn’s disease (CD) and permanent ileostomy (PI) is limited. We aimed to summarize the interventional studies related to the provision of adjunctive ostomy care in this population. Methods MEDLINE, Embase, and Cochrane CENTRAL were searched from inception to January 5, 2024. Eligible studies were non-randomized or randomized controlled trials (RCTs), or comparative cohort studies predominantly recruiting participants with CD and/or ulcerative colitis (UC) with PI assessing interventions for the management of high stoma output, disease recurrence, peristomal skin care, pouching systems, behavioral interventions, mental health support, and diet. Results Out of 3217 records, 6 were eligible and all were RCTs (n = 95). Out of these, 5 adopted a crossover design, and 1 study was a double-blind parallel-group RCT. All except 1 were published more than 20 years ago (1976-2003). Two studies exclusively included patients with UC, one included CD, and the remaining included both UC and CD. Four studies assessed pharmacological interventions (loperamide, 5-aminosalysilate [5-ASA], azodisal sodium, and budesonide), one assessed oral supplement with different osmolarities, and one assessed dietary intervention (unrefined vs refined carbohydrate). A decrease in ileostomy output was the primary outcome of interest in 4 studies. None of the studies assessed interventions for peristomal skin care, quality of life, stoma pouching systems, behavioral interventions, mental health, or CD recurrence. Conclusions This study highlights that the evidence base to inform care for patients with IBD and PI is almost non-existent. There is an urgent need for focused research in this area to inform evidence-based treatment decisions.

Year:

2024

Background Digital health monitoring may help facilitate self-management strategies when caring for patients with inflammatory bowel disease (IBD). Aims This study investigated the feasibility of implementing the MyGut health application when caring for patients with IBD and evaluated whether its use improved health outcomes. Methods We conducted a prospective trial in 2 Canadian hospitals from 2020 to 2023. Patients with IBD were recruited from gastroenterology clinics, and the MyGut application was installed onto their mobile devices. Metrics such as acceptability, satisfaction, feasibility, quality-of-life scores (measured through the short IBD questionnaire [SIBDQ]), and resource utilization were collected throughout the 1-year follow-up period. Results Of the 84 patients enrolled, 58 patients (69%) continued to use the app until the study completion. At recruitment, all 84 patients (100%) were willing to use the MyGut application after a brief tutorial. There was a significant improvement in the SIBDQ scores after 1 year of MyGut use (mean = 56.0, SD 8.85 vs 52.0, SD 9.84) (P = .012). However, only 42.9% (21/49) of the patients were willing to continue using the application after 1 year, a significant decrease compared with the 71.4% (35/49) who were willing to continue after 2 months (P = .001). No differences were observed in the number of emergency room visits/hospitalizations (P = .78) before and after 1 year of MyGut use. Conclusions This study demonstrates that patients are willing to use digital health monitoring platforms and this may lead to improved quality of life. However, sustained efforts must be made to optimize its long-term feasibility.

Year:

2024

Year:

2024

Year:

2021

Collaborators (8)

Walter Reinisch

Medical University of Vienna

AUSTRIA
View details

Remo Panaccione

Director, Inflammatory Bowel disease Unit, Professor of Medicine

University of Calgary

CANADA
View details

Parambir S Dulai

Northwestern University

UNITED STATES
View details

Yuhong Yuan

Senior Scientist

McMaster University

CANADA
View details

Virginia Solitano

Western University

CANADA
View details

Christopher Ma

Associate Professor

University of Calgary

CANADA
View details

Vipul Jairath

Professor of Medicine

Western University

CANADA
View details

Silvio Danese

Vita-Salute San Raffaele University

ITALY
View details